Literature DB >> 12391281

Regulation of the A3 adenosine receptor gene in vascular smooth muscle cells: role of a cAMP and GATA element.

R Yaar1, L M Cataldo, A Tzatsos, C E Francis, Z Zhao, K Ravid.   

Abstract

In previous studies, we reported that the level of expression of the adenylyl cyclase inhibitory A3 adenosine receptor (AR) impacts vascular tone and that rat vascular smooth muscle cells (VSMCs) coexpress the A3 AR and the adenylyl cyclase stimulatory A2a- and A2b-type ARs. In the current study, we investigated the regulation of expression of the A3 AR gene, focusing on sequences conserved in the mouse and human promoters. Transient transfection of primary cultures of rat VSMCs, using the mouse A3 AR promoter, shows that mutation of a conserved cAMP response element (CRE) significantly up-regulates promoter activity in first passage cells, whereas mutation of a conserved GATA site reduces promoter activity. This suggests that an inhibitory protein binds the CRE, whereas an enhancing factor binds the GATA sequence. Electrophoretic mobility shift assays (EMSAs) indicate that the putative CRE and GATA sites indeed bind cAMP response element modulator 1/c-Jun and the GATA6 protein, respectively. A3 AR promoter activity is significantly up-regulated in the presence of forskolin, the nonselective agonist 5'-(N-ethylcarboxamido)adenosine, or the A2a AR agonist 4-[2-[[6-amino-9(N-ethyl-beta-D-ribofuranuronamidosyl)-9H-purin-2-yl]amino]ethyl]benzenepro- panoic acid (CGS21680), reaching levels similar to those of the A3 AR promoter bearing a mutated CRE. EMSA indicates that in the presence of forskolin the binding to the CRE is inhibited, suggesting that cAMP elevation disturbs the formation of an inhibitory complex on the CRE. Finally, semiquantitative reverse transcription-polymerase chain reaction analysis reveals that endogenous A3 AR mRNA is elevated in response to forskolin. Our findings suggest the presence of a mechanism by which cAMP might control its own level in cells via regulation of genes involved in modulation of adenylyl cyclase activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12391281     DOI: 10.1124/mol.62.5.1167

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Activation of the macrophage A2b adenosine receptor regulates tumor necrosis factor-alpha levels following vascular injury.

Authors:  Hongjie Chen; Dan Yang; Shannon H Carroll; Holger K Eltzschig; Katya Ravid
Journal:  Exp Hematol       Date:  2009-05       Impact factor: 3.084

2.  Angiotensin II stimulates apoptosis via TGF-beta1 signaling in ventricular cardiomyocytes of rat.

Authors:  D Schröder; J Heger; H M Piper; G Euler
Journal:  J Mol Med (Berl)       Date:  2006-08-19       Impact factor: 4.599

Review 3.  Mechanisms of induction of adenosine receptor genes and its functional significance.

Authors:  Cynthia St Hilaire; Shannon H Carroll; Hongjie Chen; Katya Ravid
Journal:  J Cell Physiol       Date:  2009-01       Impact factor: 6.384

4.  B-Myb regulates the A(2B) adenosine receptor in vascular smooth muscle cells.

Authors:  Cynthia St Hilaire; Dan Yang; Barbara M Schreiber; Katya Ravid
Journal:  J Cell Biochem       Date:  2008-04-15       Impact factor: 4.429

5.  Lysyl oxidase propeptide inhibits smooth muscle cell signaling and proliferation.

Authors:  Paola A Hurtado; Siddharth Vora; Siddika Selva Sume; Dan Yang; Cynthia St Hilaire; Ying Guo; Amitha H Palamakumbura; Barbara M Schreiber; Katya Ravid; Philip C Trackman
Journal:  Biochem Biophys Res Commun       Date:  2007-12-03       Impact factor: 3.575

6.  Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression.

Authors:  Avivit Ochaion; Sara Bar-Yehuda; Shira Cohn; Luis Del Valle; Georginia Perez-Liz; Lea Madi; Faina Barer; Motti Farbstein; Sari Fishman-Furman; Tatiana Reitblat; Alexander Reitblat; Howard Amital; Yair Levi; Yair Molad; Reuven Mader; Moshe Tishler; Pnina Langevitz; Alexander Zabutti; Pnina Fishman
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

Review 7.  Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.

Authors:  Kevin Sek; Christina Mølck; Gregory D Stewart; Lev Kats; Phillip K Darcy; Paul A Beavis
Journal:  Int J Mol Sci       Date:  2018-12-02       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.